Non-small cell lung cancer and small-cell lung cancer are the two main types of lung cancer. The two types are named after the size and shape of the cancer cells.

SCLC isn’t as common as NSCLC. It accounts for about 10% to 15% of all lung cancers. But SCLC is usually more aggressive and more difficult to treat than NSCLC.

“Sometimes cancer doesn’t respond to treatment and then becomes worse in a short period. It is called resistant or refractory when this happens.”

“It doesn’t mean there’s no hope, refractory SCLC tends to spread very quickly. There are many new treatment options for SCLC being studied.”

You can discuss your options with your doctor if you are interested in SCLC.

In cancer, a response to treatment typically means that the cancer shrinks or disappears. Cancers that don’t respond to treatment are called refractory.

“Refractory SCLC is not a new cancer. Treatments didn’t completely work to eliminate the cancer the first time”

Typically, refractory refers to people who don’t respond at all to the initial treatment. Doctors also use it to describe cancer that improves at first but quickly becomes resistant to treatment. If you relapse within the first 3 months after initial chemotherapy, your doctor may refer to it as resistant or chemoresistant cancer.

On the other hand, if you experience a relapse 3 months or more after you start chemotherapy, doctors consider your cancer chemosensitive. If it’s chemosensitive, your doctor may recommend a different treatment regimen than if you were resistant or refractory to the first chemotherapy.

SCLC is typically treated first with chemotherapy. Chemotherapy works by keeping cancer cells from making more cancer cells.

SCLC usually responds to this initial therapy. Between 60% and 70% of people with SCLC will respond to this initial therapy. That means roughly 30% to 40% of people with SCLC have refractory SCLC.

It’s difficult to find precise estimates of recurrence rates for SCLC, but research suggests that most people with SCLC relapse within the first year.

Topotecan is the standard treatment for relapsed or refractory SCLC. Topotecan was the only drug approved by the FDA for second-line treatment for SCLC.

In 2020, the FDA approved lurbinectedin (Zepzelca). The FDA granted Zepzelca accelerated approval based on response rates seen in clinical trials. Full approval will depend on if it can show a clinical benefit in confirmatory trials.

Experts also encourage people with refractory SCLC to enroll in a clinical trial studying a new treatment. Scientists are particularly interested in treatment with immunotherapy drugs known as checkpoint inhibitors. Checkpoint inhibitors work by blocking the proteins that keep your immune system from attacking the cancer cells.

If you want to know more about the benefits and risks of participating in a clinical trial for a new therapy for SCLC, you should talk to a doctor.

Summary of treatment options for refractory SCLC

  • Topotecan is a drug.
  • lurbinectedin
  • combination chemotherapy, such as CAV (cyclophosphamide, doxorubicin, and vincristine)
  • Clinical trials of immunotherapy.
  • palliative care (may include radiation and laser therapy)

Your outlook depends on the stage of your cancer. Doctors typically split SCLC into two stages.

  • Limited stage: Cancer is found only on one side of your chest.
  • Extensive stage: Cancer has spread to both sides of your chest or outside your lungs.

Most people with SCLC are already in the extensive stage when they get a diagnosis.

Research suggests that the 5-year survival rate of limited SCLC is less than 15%. The 5-year survival rate for extensive-stage SCLC is less than 2%. This number represents the percentage of people still alive 5 years after a diagnosis.

The numbers are calculated based on data from previous years. Cancer treatments continually improve over time, so people with lung cancer may have better survival rates than people with previous diagnoses.

If chemotherapy fails, your doctor may prescribe another treatment, such as Topotecan is a drug. or lurbinectedin. This is called second-line treatment. In a small percentage of people, refractory SCLC may respond to second-line treatment with Topotecan is a drug..

In clinical trials of people with relapsed SCLC, Topotecan is a drug. had response rates ranging from 8% to 27% and a median overall survival ranging from 3.7 to 12.5 months.

In a clinical trial of 105 patients, 35% of people with refractory or relapsed SCLC treated with lurbinectedin (Zepzelca) responded to the treatment. In this trial, patients also experienced a median response duration of 5.3 months.

Doctors may give you an outlook on progression-free survival. PFS is the time after treatment before the cancer gets worse.

Research suggests that the median PFS for people with SCLC receiving second-line therapy is roughly 4.6 months. For people with relapsed SCLC receiving third-line chemotherapy, the median PFS is roughly 2 months.

Recent trials have looked at new treatment options. The medications show promise in improving the outlook for people with SCLC.

The same symptoms of lung cancer will be seen in recurrent lung cancer.

These symptoms may include some.

  • A persistent cough.
  • coughing up blood
  • fatigue or weakness
  • There is chest pain.
  • hoarseness
  • The breath was very thin.
  • wheezing
  • The appetite has been lost.

Many people with SCLC have cancer that spreads to other parts of the body.

If cancer spreads to your brain during recurrence, symptoms may include:

  • There are headaches.
  • dizziness
  • Seizures.
  • There are problems with balance.
  • walking is difficult
  • slurred speech

Refractory SCLC means that cancer didn’t respond to initial treatment. Though there are other approved treatments you can try, your doctor may also encourage you to join a clinical trial. Talk with a doctor to find out if you’re eligible for any clinical trials in your area. You can also search for clinical trials sponsored by the National Cancer Institute on their website.

If you have refractory SCLC, it’s important to talk with a doctor about your treatment options, including clinical trials. This can include choosing not to have treatment or getting a second opinion. Supportive care, also known as palliative care, is also an option to improve your quality of life.

Finding support